返回 
加入收藏
拉考沙胺与卡马西平治疗成人新诊癫痫的有效性和安全性对比
x
请在关注微信后，向客服人员索取文件
| 篇名： | 拉考沙胺与卡马西平治疗成人新诊癫痫的有效性和安全性对比 |
| TITLE： | Efficacy and safety comparison of lacosamide and carbamazepine in the treatment of adult patients with newly diagnosed epilepsy |
| 摘要： | 目的 比较拉考沙胺（LCM）与卡马西平（CAR）单药治疗成人新诊癫痫患者的有效性和安全性。方法采用回顾性分析方法，根据用药方案的不同，将2020年9月－2022年6月河南大学淮河医院神经内科收治的新诊癫痫患者（84例）分为对照组（40例，接受CAR治疗）和观察组（44例，接受LCM治疗），比较两组患者的总有效率、癫痫发作频率、血脂水平和不良事件（AEs）发生情况。结果治疗后第1个月，观察组患者的总有效率（63.64%）与对照组（55.00%）比较，差异无统计学意义（P＞0.05）；两组患者的癫痫发作频率均较治疗前显著减少（P＜0.05），但组间比较差异无统计学意义（P＞0.05）。治疗后第3个月，观察组患者的总有效率（90.91%）显著高于对照组（67.50%，P＜0.05）；两组患者的癫痫发作频率亦较治疗前显著减少，且观察组显著少于对照组（P＜0.05）。治疗后第3个月，对照组患者的TC、TG、LDL-C水平以及观察组患者的LDL-C水平均较同组治疗前显著升高，且观察组患者的TC、TG、LDL-C水平均显著低于对照组（P＜0.05）。观察组患者的AEs发生率（15.91%）与对照组（17.50%）比较，差异无统计学意义（P＞0.05）。结论LCM和CAR在成人新诊癫痫患者的治疗中均具有一定效果，均可降低患者的癫痫发作频率，且安全性相当。同时，LCM的长期疗效优于CAR，对患者血脂水平的影响小于CAR。 |
| ABSTRACT： | OBJECTIVE To compare the efficacy and safety of lacosamide （LCM） and carbamazepine （CAR） as monotherapy in the treatment of adult patients with newly diagnosed epilepsy. METHODS By methods of retrospective analysis， 84 adult patients with newly diagnosed epilepsy， were admitted to the Department of Neurology， Huaihe Hospital of Henan University during Sept. 2020-Jun. 2022， were divided into the control group （40 cases， receiving CAR treatment） and the observation group （44 cases， receiving LCM treatment） according to different medication regimens. Total response rate， epilepsy seizure frequency， blood lipid levels， and the occurrence of adverse events （AEs） of patients were compared between the 2 groups. RESULTS In the first month after treatment， there was no statistically significant difference in the total response rate between the observation group （63.64%） and the control group （55.00%， P＞0.05）； the frequency of epilepsy seizure in both groups was significantly reduced compared to before treatment （P＜0.05）， but there was no statistically significant difference between 2 groups （P＞0.05）. In the third month after treatment， the total response rate of the observation group （90.91%） was significantly higher than control group （67.50%， P＜0.05）； the frequencies of epilepsy seizure in both groups were significantly reduced compared to before treatment， and the observation group was significantly lower than the control group （P＜0.05）. In the third month after treatment， the levels of total cholesterol （TC）， triglyceride （TG） and low-density lipoprotein cholestrol （LDL-C） in the control group and the level of LDL-C in the observation group were significantly higher than before treatment， and the levels of TC， TG and LDL-C in the observation group were significantly lower than those in the control group （P＜0.05）. There was no statistically significant difference in the incidence of AEs between the observation group （15.91%） and the control group （17.50%， P＞0.05）. CONCLUSIONS Both LCM and CAR have certain effects in the treatment of newly diagnosed epilepsy in adults， which can reduce the frequency of epilepsy seizure in patients and have comparable safety. Meanwhile， LCM has better long-term efficacy than CAR in treating newly diagnosed epilepsy in adults， and its impact on the patient’s blood lipid is smaller than CAR. |
| 期刊： | 2024年第35卷第04期 |
| 作者： | 郭夏青；李郭飞；孙玉华；郑东琳 |
| AUTHORS： | GUO Xiaqing，LI Guofei，SUN Yuhua，ZHENG Donglin |
| 关键字： | 拉考沙胺；卡马西平；新诊癫痫；成人患者；有效性；安全性 |
| KEYWORDS： | lacosamide； carbamazepine； newly diagnosed |
| 阅读数： | 31 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
